Breaking News
LumiraDx Achieves CE Mark for COVID-19 Antigen Test on Amira, its New Low-Cost Testing System
LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced that it has achieved CE Mark for the Amira System, its new testing system that provides low-cost, highly sensitive COVID-19 testing. The Amira Analyzer reads the included Amira SARS-CoV-2 Ag test strips and returns a result in just 15 minutes. The Amira Analyzer condenses technology from large laboratory analyzers into a portable instrument, comparable in size and weight to a deck of playing cards, that delivers high performing testing in minutes. The initial CE Mark for the Amira System covers professional use at the point of care. However, the company plans to seek additional regulatory approvals and authorizations for the Amira System, including those required for non-professional, over the counter use, to provide value for home, events, workplace, and travel testing.
The microfluidic technology in the Amira SARS-CoV-2 Ag test delivers excellent testing performance. The test has a positive percent agreement of 90.00% and a negative percent agreement of 99.31% versus RT-PCR in symptomatic individuals, based on clinical data collected 0-10 days since symptom onset. Within this cohort, the Amira SARS-CoV-2 Ag test showed sensitivity of 95.6% up to a CT of 30 indicating high coverage of potentially infectious individuals.
Ron Zwanziger, LumiraDx’s Chief Executive Officer commented, “The Amira System brings a unique combination of features to the market. It is one of the only COVID-19 testing solutions on the market that can offer highly accurate, objectively read results with the rapid turnaround time and low price of many lateral flow tests. Frequent testing has become a part of many of our lives in order to limit the spread of the virus. However, without trusted results, many testing protocols do not accurately protect patients, employees, and families.”
The Amira System will be commercially available in Europe shortly as a starter kit with one analyzer and 200 Amira SARS CoV-2 Ag test strips.
People In This Post
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more
Senhwa Biosciences Received Taiwan FDA IND Approval for Phase II Study of Silmitasertib in Patients with Moderate to Severe COVID-19
Senhwa Biosciences, a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and […]
Pneumagen Further Strengthens IP Protection for Lead Product Neumifil with Granting of US Composition of Matter Patent
Pneumagen, a clinical-stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for the prophylaxis […]
ECCMID 2023: Shionogi to Present Data Showing COVID-19 Symptom Recurrence is Not Associated with Ensitrelvir Treatment
Shionogi today announced that two late-breaking poster presentations featuring new results from the Phase 3 […]
PharmaJet Announces Clinical Results from Scancell’s COVID-19 DNA Vaccine Study Exclusively Administered with Needle-free Precision Delivery Systems
PharmaJet, a company engineering precision delivery systems that may overcome the challenges of nucleic acid […]
Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue
Axcella Therapeutics, a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted […]
U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax’ COVID-19 Vaccine
Novavax, a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, […]
Roche launches COVID-19 PCR Test to Detect the Fast Spreading XBB.1.5 Omicron Sub-variant
Roche and its subsidiary TIB Molbiol have developed a COVID-19 PCR test for researchers that […]
Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients
Eloxx Pharmaceuticals, a leader in ribosomal RNA-targeted genetic therapies for rare diseases, have announced the […]
Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS
Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, […]
DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board
DEM BioPharma, an immune-oncology company developing therapies that target signals on cancer cells and myeloid […]
Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera
Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today […]
Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic
Vyriad announces an expansion of a Phase 1 investigator-initiated trial at Mayo Clinic evaluating the […]
Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders
Astellas Pharma and Cullgen have announced a research collaboration and exclusive option agreement to discover […]
Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program
Auxilius Pharma has consolidated its funding of $1 Million for developing its lead asset, AUX-001, […]